Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

    October 2018 in “ Clinical & Translational Oncology ”
    Cristina Grávalos, O. Sanmartín, Alfonso Gúrpide … Rafael Botella
    Studysummary This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. RASopathic Alopecia: Hair Changes Associated with Vemurafenib Therapy Journal of The American Academy of Dermatology · 2015
    2. Cutaneous Adverse Effects of Targeted Therapies Journal of the American Academy of Dermatology · 2015
    3. Cutaneous Adverse Effects of Targeted Therapies Journal of the American Academy of Dermatology · 2015
    4. Skin Toxicity Caused by EGFR Antagonists: An Autoinflammatory Condition Triggered by Deregulated IL-1 Signaling? Journal of Cellular Physiology · 2008
    5. Comparison of Epidermal Growth Factor Binding and Receptor Distribution in Normal Human Epidermis and Epidermal Appendages Journal of Investigative Dermatology · 1984

    Related research 3

    1. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar PubMed · 2021
    2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar Acta dermatovenerologica Croatica · 2021
    3. Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology Clinical & Translational Oncology · 2018